Literature DB >> 30773983

Effectiveness of Prehospital Dual Sequential Defibrillation for Refractory Ventricular Fibrillation and Ventricular Tachycardia Cardiac Arrest.

Lauren R Beck, Daniel G Ostermayer, Joseph N Ponce, Saranya Srinivasan, Henry E Wang.   

Abstract

Objective: Dual sequential defibrillation (DSD) - successive defibrillations with two defibrillators - offers a novel approach to refractory ventricular fibrillation (RVF) and tachycardia (VF/VT). While associated with rescue shock success, the effect of DSD upon out-of-hospital cardiac arrest (OHCA) is unknown. We evaluated the association of DSD with survival after refractory VF/VT OHCA.
Methods: We used data from a large metropolitan fire-based EMS service. We included all adult OHCA during 2013-2016 with ≥3 standard defibrillations. Physicians authorized subsequent DSD use by two separate defibrillators (PhysioControl LIFEPAK® 12/15) with pads placed anterior-lateral and anterior-posterior. Evaluated outcomes included return of spontaneous circulation (ROSC), survival to hospital admission, survival to 72 hours, and survival to hospital discharge. Using multivariable logistic regression, we evaluated the association between defibrillation type and OHCA outcomes, adjusting for patient demographics and event characteristics.
Results: We included 310 patients in the analysis, 71 patients receiving DSD and 239 receiving conventional defibrillation. Patient demographics and event characteristics were similar between both groups. ROSC was lower for DSD than standard defibrillation: 39.4% vs. 60.3%, adjusted OR 0.46 (95% CI: 0.25-0.87). There were no differences in survival to hospital admission (35.2% vs. 49.2%, adjusted OR 0.57 [95% CI: 0.30-1.08]), survival to 72 hours (21.4% vs. 32.3%, adjusted OR 0.52 [95% CI: 0.26-1.10]), or survival to hospital discharge (14.3% vs. 20.9%, adjusted OR 0.63 [95% CI: 0.27-1.45]). Conclusions: Compared with conventional defibrillation, DSD was associated with lower odds of prehospital ROSC. Defibrillation type was not associated with other OHCA endpoints. DSD may not be beneficial in refractory VF/VT OHCA.

Entities:  

Keywords:  cardiac arrest; defibrillation; double sequential defibrillation; refractory ventricular fibrillation

Year:  2019        PMID: 30773983     DOI: 10.1080/10903127.2019.1584256

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  6 in total

1.  Prehospital Double Defibrillation for Refractory Ventricular Fibrillation: A Scoping Review Protocol.

Authors:  Dennis Miraglia; Lourdes A Miguel
Journal:  J Innov Card Rhythm Manag       Date:  2020-06-15

Review 2.  The Evolving Role of Esmolol in Management of Pre-Hospital Refractory Ventricular Fibrillation; a Scoping Review.

Authors:  Dennis Miraglia; Lourdes A Miguel; Wilfredo Alonso
Journal:  Arch Acad Emerg Med       Date:  2020-02-25

3.  Association between the number of prehospital defibrillation attempts and neurologic outcomes in out-of-hospital cardiac arrest patients without on-scene return of spontaneous circulation.

Authors:  Seulki Choi; Tae Han Kim; Ki Jeong Hong; Joo Jeong; Young Sun Ro; Kyoung Jun Song; Sang Do Shin
Journal:  Clin Exp Emerg Med       Date:  2021-03-31

4.  Feasibility of prehospital esmolol for refractory ventricular fibrillation.

Authors:  Casey Patrick; Remle P Crowe; Brad Ward; Ali Mohammed; Kelley Rogers Keene; Robert Dickson
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-04-09

Review 5.  [Adult advanced life support].

Authors:  Jasmeet Soar; Bernd W Böttiger; Pierre Carli; Keith Couper; Charles D Deakin; Therese Djärv; Carsten Lott; Theresa Olasveengen; Peter Paal; Tommaso Pellis; Gavin D Perkins; Claudio Sandroni; Jerry P Nolan
Journal:  Notf Rett Med       Date:  2021-06-08       Impact factor: 0.826

6.  Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

Authors:  Jasmeet Soar; Katherine M Berg; Lars W Andersen; Bernd W Böttiger; Sofia Cacciola; Clifton W Callaway; Keith Couper; Tobias Cronberg; Sonia D'Arrigo; Charles D Deakin; Michael W Donnino; Ian R Drennan; Asger Granfeldt; Cornelia W E Hoedemaekers; Mathias J Holmberg; Cindy H Hsu; Marlijn Kamps; Szymon Musiol; Kevin J Nation; Robert W Neumar; Tonia Nicholson; Brian J O'Neil; Quentin Otto; Edison Ferreira de Paiva; Michael J A Parr; Joshua C Reynolds; Claudio Sandroni; Barnaby R Scholefield; Markus B Skrifvars; Tzong-Luen Wang; Wolfgang A Wetsch; Joyce Yeung; Peter T Morley; Laurie J Morrison; Michelle Welsford; Mary Fran Hazinski; Jerry P Nolan
Journal:  Resuscitation       Date:  2020-10-21       Impact factor: 5.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.